Our experience in treating chronic active HCV infection in patients with sickle cell anemia is limited.We are giving either peg-interferon monotherapy or combination therapy (peg-interferon+low dose Ribavirin ),also the role of protease inhibitors eg: Telaprivir and Boceprivir in treating such group of patients is not well understood.
Clinical trial results show that Zepatier (elbasvir/grazoprevir) is highly effective against hepatitis C virus (HCV) infection in sickle cell disease patients and others with inherited blood disorders.
The study with these findings, “Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study,” was published in the journal Hepatology.